Work

Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies

Year: 2023

Type: article

Study design: Clinical Trial

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/j.clml.2023.05.002

Authors: Manish R. Patel, William Donnellan, Michael Byrne, Adam S. Asch, Amer M. Zeidan, Maria R. Baer, Amir T. Fathi, Andrew T. Kuykendall, Fred Zheng, Chris Walker, Lulu Cheng, Cindy Marando, Michael R. Savona

Institutions: Florida Cancer Specialists & Research Institute, Tennessee Oncology, Vanderbilt University, Vanderbilt-Ingram Cancer Center, OU Health Stephenson Cancer Center, Yale Cancer Center, Yale University, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Harvard University, Massachusetts General Hospital, Moffitt Cancer Center, Incyte (United States)

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Cancer Institute

Award: UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANT

OpenAlex ID: W4376956398

FWCI: 2.881

Cites: 40

Cited by: 14

Related to: 10